HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials
| Autor: | Tadeusz Pienkowski, Dennis J. Slamon, Ivonne Villalobos, Yanling Ma, John R. Mackey, Marc Buyse, Nicholas J. Robert, Vicente Valero, E. Quinaux, Wolfgang Eiermann, Denice D. Tsao-Wei, John Crown, Michael F. Press, Mary-Ann Lindsay, Guido Sauter, Martina Mirlacher, Miguel Martín, Hélène Fourmanoir, V. Bee-Munteanu, Anaamika Campeau |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.diagnostic_test business.industry Hazard ratio medicine.disease Bioinformatics Clinical trial Breast cancer Trastuzumab Internal medicine HER2 Gene Amplification medicine Fish Copy-number variation skin and connective tissue diseases business neoplasms medicine.drug Fluorescence in situ hybridization |
| Zdroj: | Journal of Clinical Oncology. 34:515-515 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 515Background: ASCO-CAP recently recommended further changes to evaluation of HER2 gene amplification by FISH. We retrospectively assessed the impact of the guidelines using annotated BCIRG-005, BCIRG-006, and BCIRG-007 clinical trial data for which we have detailed outcomes. Methods: HER2 FISH status of BCIRG-005/006/007 breast cancers was re-evaluated according to 2013/2014 ASCO-CAP guidelines, which designate five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell; group 1 (“ISH-positive”): HER2-to-CEP17 ratio ≥2.0, average HER2 copies ≥4.0; group2 (“ISH-positive”): ratio ≥2.0, copies |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|